Meeting
2019 ASCO Annual Meeting
NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
Authors
Mairead Geraldine McNamara
Institute of Cancer Sciences, University of Manchester, Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, United Kingdom
Mairead Geraldine McNamara , Jayne Swain , Zoe Craig , Jonathan Wadsley , Nicholas Reed , Olusola Olusesan Faluyi , Angela Lamarca , Richard Hubner , Wasat Mansoor , Debashis Sarker , Helen C Howard , David A. Cairns , Tim Meyer , Juan W. Valle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
10996604
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS4158)
DOI
10.1200/JCO.2019.37.15_suppl.TPS4158
Abstract #
TPS4158
Poster Bd #
254b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).
First Author: Mairead Geraldine McNamara
Poster
2022 ASCO Quality Care Symposium
Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy.
First Author: Zoe Craig
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).
First Author: Sherise C. Rogers
Poster
2019 ASCO Annual Meeting
An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).
First Author: Ming-Huang Chen